Taysha Gene Therapies Files 8-K on Financials
Ticker: TSHA · Form: 8-K · Filed: May 15, 2025 · CIK: 1806310
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Taysha Gene Therapies dropped an 8-K detailing its financial condition and results of operations.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas.
Why It Matters
This filing provides investors with crucial updates on Taysha Gene Therapies' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (8-K) and does not contain new material events or significant changes.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
- 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (location) — Principal Executive Offices
- 001-39536 (company) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Taysha Gene Therapies, Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2025.
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
Taysha Gene Therapies, Inc.'s principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the SEC file number for Taysha Gene Therapies, Inc.?
The SEC file number for Taysha Gene Therapies, Inc. is 001-39536.
What is the Standard Industrial Classification for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification for Taysha Gene Therapies, Inc. is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).